A NOVEL POINT-OF-CARE PLATELET FUNCTION ANALYZER

描述(申请人提供)：冠心病(CHD)和中风仍然是美国发病率和死亡率的主要原因之一，而血小板在CHD/中风中起着重要作用。因此，抗血小板药物的使用有助于预防或治疗此类血管疾病。尽管大量患者常规使用抗血小板药物，但抗血小板治疗的疗效很少在每个患者中得到监测。大多数患者被开出固定剂量的处方，没有努力建立治疗效果，缺乏适当的战略使个人监测和调整剂量以确保足够的保护。多达30%的患者可能对阿司匹林和氯吡格雷等常用抗血小板药物的标准剂量产生抗药性，这进一步强调了监测抗血小板治疗的必要性。目前用于评估血小板功能的方法既繁琐又耗时(实验室方法)，或者相对昂贵、不可靠，并且只能提供间接/不完整的测量(当前的护理点仪器)，因此缺乏敏感性。血栓公司在美国国立卫生研究院的资助下，开发了一种评估全血中血小板功能的新方法。功能版本的血栓型血小板功能分析仪(TPFA)经受住了实验室和有限的临床测试的严格考验，可以检测血小板功能异常，并识别可能对标准剂量的抗血小板药物有抵抗力的患者。通过这项申请，研究人员请求支持，以继续他们的努力：1)使TPFA成为一种成本效益高、方便和多功能的护理终点工具，2)寻求FDA的批准，为其上市做准备，以及3)证明单独定制剂量的抗血小板药物(或联合用药)将导致更好的治疗效果，减少副作用，并产生更好的结果。申请者在他们的发展道路上处于一个独特的点，在这个点上，他们所申请的资金将允许他们将该设备推向市场。这种方便、经济实惠的护理点血小板功能分析仪的推出将使为每个人量身定做抗血小板治疗成为可能，并改善结果。

DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and stroke remain 1 of the major causes of morbidity and mortality in the US, and platelets play a major role in CHD/stroke. Thus, the use of antiplatelet drugs is helpful in the prevention or treatment of such vascular disorders. Despite routine use of antiplatelet agents in a large number of patients, the efficacy of antiplatelet therapy is rarely monitored in each patient. Most patients are prescribed a fixed dose with no effort to establish therapeutic efficacy, and the lack of suitable strategies precludes individual monitoring and adjustment of dosage to ensure adequate protection. The need for monitoring antiplatelet therapy is further accentuated by the fact that as many as 30% of patients may be resistant to standard dosages of commonly used antiplatelet drugs such as aspirin and clopidogrel. The current methods for the assessment of platelet function are cumbersome and time-consuming (laboratory methods), or relatively expensive, unreliable and offer only an indirect/incomplete measure (current point-of care instruments), and therefore lack sensitivity. Thrombodyne Inc. has developed, with funding from NIH, a novel approach to assess platelet function in whole blood. A functional version of the Thrombodyne Platelet Function Analyzer (TPFA) has withstood the rigors of laboratory and limited clinical testing, and detects platelet function abnormalities and identifies patients who may be resistant to standard doses of antiplatelet agents. Through this application, the investigators request support to sustain their efforts to: 1) make TPFA a cost-effective, convenient and versatile point-of-care instrument, 2) to seek FDA approvals to prepare it for marketing, and 3) to demonstrate that individually tailored dosing of antiplatelet agent (or combination of agents) would lead to better therapeutic efficacy, reduce side effects, and result in better outcomes. The applicants are at a unique point in their development path where the requested funding would allow them to take the device to market. The introduction of this convenient, cost-effective point-of-care platelet function analyzer would make it possible to tailor antiplatelet therapy for each individual and improve outcomes.